García-Fadrique Alfonso, Mehta Akash, Mohamed Faheez, Dayal Sanjeev, Cecil Tom, Moran Brendan J
General and Digestive Surgery, Valencian Institute of Oncology, Valencia, Spain.
Peritoneal Malignancy Institute and Colorectal Surgery, Basingstoke and North Hampshire Hospitals, Basingstoke, UK.
J Gastrointest Oncol. 2017 Oct;8(5):915-924. doi: 10.21037/jgo.2017.08.01.
Peritoneal mesothelioma (PM) is an uncommon but a serious, and often, fatal primary peritoneal tumour, with increasing incidence worldwide. Conventional systemic chemotherapy, generally based on experience with pleural mesothelioma, usually has disappointing results considering PM as a terminal condition. Patients usually present with non-specific symptoms of abdominal distension and pain making the diagnosis challenging. As PM is confined to the abdomen for all, or much, of its clinical course, a multimodality treatment combining cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a new standard of care, and has been reported to achieve promising survival outcomes and local disease control in selected patients with PM. This review updates the presentation, diagnosis, classification and treatment strategies for PM.
腹膜间皮瘤(PM)是一种罕见但严重且往往致命的原发性腹膜肿瘤,在全球范围内发病率呈上升趋势。传统的全身化疗通常基于胸膜间皮瘤的经验,鉴于PM被视为终末期疾病,其效果通常令人失望。患者通常表现为腹胀和疼痛等非特异性症状,这使得诊断具有挑战性。由于PM在其整个或大部分临床病程中局限于腹部,一种将细胞减灭术(CRS)与腹腔内热灌注化疗(HIPEC)相结合的多模式治疗已成为新的标准治疗方法,并且据报道在部分PM患者中可实现有前景的生存结果和局部疾病控制。本综述更新了PM的临床表现、诊断、分类和治疗策略。